FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2613907595> ?p ?o ?g. }

• W2613907595 endingPage "138" @default.
• W2613907595 startingPage "129" @default.
• W2613907595 abstract "Background A meta-analysis of the effects of HER2 status, specifically within the first 2–3 years of adjuvant endocrine therapy, has the potential to inform patient selection for upfront aromatase inhibitor (AI) therapy or switching strategy tamoxifen followed by AI. The pre-existing standardisation of methodology for HER2 (immunohistochemistry/fluorescence in situ hybridization) facilitates analysis of existing data for this key marker. Methods Following a prospectively designed statistical analysis plan, patient data from 3 phase III trials Arimidex, Tamoxifen, Alone or in Combination Trial (ATAC), Breast International Group (BIG) 1-98 and Tamoxifen Exemestane Adjuvant Multicentre Trial (TEAM)] comparing an AI to tamoxifen during the first 2–3 years of adjuvant endocrine treatment were collected and a treatment-by-marker analysis of distant recurrence-free interval-censored at 2–3 years treatment – for HER2 status × AI versus tamoxifen treatment was performed to address the clinical question relating to efficacy of ‘upfront’ versus ‘switch’ strategies for AIs. Results A prospectively planned, patient-level data meta-analysis across 3 trials demonstrated a significant treatment (AI versus tamoxifen) by marker (HER2) interaction in a multivariate analysis; (interaction hazard ratio [HR] = 1.61, 95% CI 1.01–2.57; p < 0.05). Heterogeneity between trials did not reach statistical significance. The HER2 negative (HER2−ve) group gained greater benefit from AI versus tamoxifen (HR = 0.70, 95% CI 0.56–0.87) than the HER2-positive (HER2+ve) group (HR = 1.13, 95% CI 0.75–1.71). However, the small number of HER2+ve cases (n = 1092 across the 3 trials) and distant recurrences (n = 111) may explain heterogeneity between trials. Conclusions A patient-level data meta-analysis demonstrated a significant interaction between HER2 status and treatment with AI versus tamoxifen in the first 2–3 years of adjuvant endocrine therapy. Patients with HER2−ve cancers experienced improved outcomes (distant relapse) when treated with upfront AI rather than tamoxifen, whilst patients with HER2+ve cancers fared no better or slightly worse in the first 2–3 years. However, the small number of HER2+ve cancers/events may explain a large degree of heterogeneity in the HER2+ve groups across all 3 trials. Other causes, perhaps related to subtle differences between AIs, cannot be excluded and warrant further exploration." @default.
• W2613907595 created "2017-05-19" @default.
• W2613907595 creator A5017334876 @default.
• W2613907595 creator A5020035024 @default.
• W2613907595 creator A5022237789 @default.
• W2613907595 creator A5023115832 @default.
• W2613907595 creator A5026031837 @default.
• W2613907595 creator A5038448622 @default.
• W2613907595 creator A5042549003 @default.
• W2613907595 creator A5058767202 @default.
• W2613907595 creator A5061698687 @default.
• W2613907595 creator A5070904518 @default.
• W2613907595 creator A5073613763 @default.
• W2613907595 creator A5080138909 @default.
• W2613907595 creator A5082393642 @default.
• W2613907595 creator A5083334188 @default.
• W2613907595 creator A5088697304 @default.
• W2613907595 creator A5091359426 @default.
• W2613907595 date "2017-07-01" @default.
• W2613907595 modified "2023-10-16" @default.
• W2613907595 title "HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2" @default.
• W2613907595 cites W1531964529 @default.
• W2613907595 cites W1654271173 @default.
• W2613907595 cites W1973914781 @default.
• W2613907595 cites W1988142400 @default.
• W2613907595 cites W1997622817 @default.
• W2613907595 cites W2015473392 @default.
• W2613907595 cites W2020016182 @default.
• W2613907595 cites W2021723847 @default.
• W2613907595 cites W2022244117 @default.
• W2613907595 cites W2030206926 @default.
• W2613907595 cites W2035810660 @default.
• W2613907595 cites W2040521377 @default.
• W2613907595 cites W2043605505 @default.
• W2613907595 cites W2043994334 @default.
• W2613907595 cites W2062713892 @default.
• W2613907595 cites W2090855460 @default.
• W2613907595 cites W2098184866 @default.
• W2613907595 cites W2101979288 @default.
• W2613907595 cites W2121656289 @default.
• W2613907595 cites W2131964282 @default.
• W2613907595 cites W2139023087 @default.
• W2613907595 cites W2140840142 @default.
• W2613907595 cites W2157768953 @default.
• W2613907595 cites W2161428561 @default.
• W2613907595 cites W2163655381 @default.
• W2613907595 cites W2214665719 @default.
• W2613907595 cites W4234081105 @default.
• W2613907595 doi "https://doi.org/10.1016/j.ejca.2017.03.033" @default.
• W2613907595 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28494403" @default.
• W2613907595 hasPublicationYear "2017" @default.
• W2613907595 type Work @default.
• W2613907595 sameAs 2613907595 @default.
• W2613907595 citedByCount "18" @default.
• W2613907595 countsByYear W26139075952017 @default.
• W2613907595 countsByYear W26139075952018 @default.
• W2613907595 countsByYear W26139075952019 @default.
• W2613907595 countsByYear W26139075952020 @default.
• W2613907595 countsByYear W26139075952021 @default.
• W2613907595 countsByYear W26139075952022 @default.
• W2613907595 countsByYear W26139075952023 @default.
• W2613907595 crossrefType "journal-article" @default.
• W2613907595 hasAuthorship W2613907595A5017334876 @default.
• W2613907595 hasAuthorship W2613907595A5020035024 @default.
• W2613907595 hasAuthorship W2613907595A5022237789 @default.
• W2613907595 hasAuthorship W2613907595A5023115832 @default.
• W2613907595 hasAuthorship W2613907595A5026031837 @default.
• W2613907595 hasAuthorship W2613907595A5038448622 @default.
• W2613907595 hasAuthorship W2613907595A5042549003 @default.
• W2613907595 hasAuthorship W2613907595A5058767202 @default.
• W2613907595 hasAuthorship W2613907595A5061698687 @default.
• W2613907595 hasAuthorship W2613907595A5070904518 @default.
• W2613907595 hasAuthorship W2613907595A5073613763 @default.
• W2613907595 hasAuthorship W2613907595A5080138909 @default.
• W2613907595 hasAuthorship W2613907595A5082393642 @default.
• W2613907595 hasAuthorship W2613907595A5083334188 @default.
• W2613907595 hasAuthorship W2613907595A5088697304 @default.
• W2613907595 hasAuthorship W2613907595A5091359426 @default.
• W2613907595 hasBestOaLocation W26139075952 @default.
• W2613907595 hasConcept C121608353 @default.
• W2613907595 hasConcept C126322002 @default.
• W2613907595 hasConcept C143998085 @default.
• W2613907595 hasConcept C207103383 @default.
• W2613907595 hasConcept C2775860665 @default.
• W2613907595 hasConcept C2777176818 @default.
• W2613907595 hasConcept C2777863537 @default.
• W2613907595 hasConcept C44249647 @default.
• W2613907595 hasConcept C530470458 @default.
• W2613907595 hasConcept C535046627 @default.
• W2613907595 hasConcept C71924100 @default.
• W2613907595 hasConcept C95190672 @default.
• W2613907595 hasConceptScore W2613907595C121608353 @default.
• W2613907595 hasConceptScore W2613907595C126322002 @default.
• W2613907595 hasConceptScore W2613907595C143998085 @default.
• W2613907595 hasConceptScore W2613907595C207103383 @default.
• W2613907595 hasConceptScore W2613907595C2775860665 @default.
• W2613907595 hasConceptScore W2613907595C2777176818 @default.
• W2613907595 hasConceptScore W2613907595C2777863537 @default.

• next